Evidence map›Paper›PMID 36997667›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2023

Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure.

Marie-Sophie L Y de Koning, Johanna E Emmens, Esteban Romero-Hernández, Arno R Bourgonje, Solmaz Assa, Sylwia M Figarska, John G F Cleland, Nilesh J Samani, Leong L Ng, Chim C Lang and 9 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 7 countries.

Marie-Sophie L Y de KoningDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands. m.s.l.y.de.koning@umcg.nl.ORCID http://orcid.org/0000-0001-9842-4861
Johanna E EmmensDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
Esteban Romero-HernándezFaculty of Medicine, Institute of Biomedical Science, University of Chile, Santiago, Chile.
Arno R BourgonjeDepartment of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Solmaz AssaDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
Sylwia M FigarskaDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
John G F ClelandNational Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, UK.
Nilesh J SamaniDepartment of Cardiovascular Sciences, University of Leicester, NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
Leong L NgDepartment of Cardiovascular Sciences, University of Leicester, NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
Chim C LangDivision of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK.
Marco MetraDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Institute of Cardiology, University of Brescia, Brescia, Italy.
Gerasimos S FilippatosSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Dirk J van VeldhuisenDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
Stefan D AnkerDepartment of Cardiology (CVK), Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany.
Kenneth DicksteinUniversity of Bergen, Stavanger University Hospital, Bergen, Norway.
Adriaan A VoorsDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
Erik LipsicDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
Harry van GoorDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Pim van der HarstDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
University Medical Center Groningen · NLUniversity of Leicester · GBGerman Centre for Cardiovascular Research · DEHarefield Hospital · GBNational and Kapodistrian University of Athens · GRStavanger University Hospital · NOUniversity of Brescia · ITUniversity of Chile · CLUniversity of Dundee · GB

Funding

European Commission EudraCT 2010-020808-29European Commission FP7-242209-BIOSTAT-CHF
6 · The paper itself

Abstract

backgroundOxidative stress may be a key pathophysiological mediator in the development and progression of heart failure (HF). The role of serum-free thiol concentrations, as a marker of systemic oxidative stress, in HF remains largely unknown.

objectiveThe purpose of this study was to investigate associations between serum-free thiol concentrations and disease severity and clinical outcome in patients with new-onset or worsening HF.

methodsSerum-free thiol concentrations were determined by colorimetric detection in 3802 patients from the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF). Associations between free thiol concentrations and clinical characteristics and outcomes, including all-cause mortality, cardiovascular mortality, and a composite of HF hospitalization and all-cause mortality during a 2-years follow-up, were reported.

resultsLower serum-free thiol concentrations were associated with more advanced HF, as indicated by worse NYHA class, higher plasma NT-proBNP (P < 0.001 for both) and with higher rates of all-cause mortality (hazard ratio (HR) per standard deviation (SD) decrease in free thiols: 1.253, 95% confidence interval (CI): 1.171-1.341, P < 0.001), cardiovascular mortality (HR per SD: 1.182, 95% CI: 1.086-1.288, P < 0.001), and the composite outcome (HR per SD: 1.058, 95% CI: 1.001-1.118, P = 0.046).

conclusionsIn patients with new-onset or worsening HF, a lower serum-free thiol concentration, indicative of higher oxidative stress, is associated with increased HF severity and poorer prognosis. Our results do not prove causality, but our findings may be used as rationale for future (mechanistic) studies on serum-free thiol modulation in heart failure. Associations of serum-free thiol concentrations with heart failure severity and outcomes.

Indexed as

Heart FailureChronic DiseaseHumansOxidative StressPatient AcuityPrognosisStroke VolumeSulfhydryl CompoundsSulfhydryl CompoundsHeart failureOxidative stressRedox statusSulfhydryl groupsThiols

Identifiers

PMID36997667
PMCPMC10062262
OpenAlexW4362457706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.